Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed non-small cell lung cancer~  * Locally advanced (stage III) disease~ * Unresectable disease~* Candidate for concurrent definitive chemotherapy and thoracic radiotherapy, as determined by the treating physician~* No malignant pleural effusion~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count \> 1,500/mm³~* Platelet count \> 100,000/mm³~* Bilirubin ≤ 1.5 mg/dL~* AST or ALT ≤ 2 times upper limit of normal (ULN)~* Creatinine ≤ 1.5 times ULN~* FEV_1 \> 600 cc~* Not pregnant or nursing~* Negative pregnancy test~* No weight loss \> 10% within the past 6 months~* No known HIV disease~PRIOR CONCURRENT THERAPY:~* No prior thoracic radiotherapy~* No prior HIV protease inhibitors~* More than 5 years since prior chemotherapy~* At least 3 weeks since prior exploratory thoracotomy~* No concurrent medications that would preclude nelfinavir administration, including any of the following:~  * Amiodarone~ * Quinidine~ * Rifampin~ * Dihydroergotamine~ * Ergonovine~ * Ergotamine~ * Methylergonovine~ * Hypericum perforatum (St. John's wort)~ * Lovastatin~ * Simvastatin~ * Pimozide~ * Midazolam~ * Triazolam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): Nelfinavir

Based on this trial design, predict the completion outcome and termination type (if applicable).